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SUMMARY Background
For thyroid nodules that are classified as indeterminate on fine-needle aspiration (FNA) biopsy, molecular testing has been used to determine whether a nodule is likely to be benign or malignant. Many endocrinologists would recommend that nodules classified as indeterminate should be resected. For the indeterminate category of atypia of undetermined significance (AUS)/follicular lesion of undetermined significance (FLUS) that was postulated to have a 5% to 15% risk of malignancy, molecular testing has been used for guidance in management. The two molecular approaches used currently are gene mutation panel testing (GMP) for making a positive diagnosis of malignancy and gene expression classifier testing (GEC), which has a high negative predictive value (1, 2) . It may be ideal to apply both methods to indeterminate nodules, but there are significant cost considerations. The current study is a theoretical analysis of the cost-effectiveness of these molecular methods in contrast with diagnostic thyroidectomy without GMP or GEC from both a U.S. and a Canadian perspective.
Methods
A patient microsimulation method was constructed to compare the lifetime cost-effectiveness of five strategies for patients with AUS nodules: (1) routine GEC; (2) GEC followed by selective GMP; (3) routine GMP; (4) routine GMP followed by selective GEC; (5) diagnostic thyroid lobectomy. The GMP is the panel of 7 oncogenes (1) and the GEC is the 142-gene classifier (2) . The microsimulation method follows each patient through the simulation. For example, in strategy 2, if the gene expression classifier is benign, then the patient is observed; if the GEC is suspicious, the patient undergoes a gene mutation panel; if the GMP is positive, the patient has total thyroidectomy; if the GMP is negative, the patient has a diagnostic lobectomy.
There are model parameters for complications, recurrence if diagnosis is delayed, and mortality. Cost estimates are based on Medicare payments for U.S. patients or on the Canadian health care system for Canadians with adjustment for the relative value of the respective dollars in U.S. dollars. Quality-adjusted life years (QALY) were the measure of effectiveness.
Results
From the U.S. perspective, the use of routine GEC followed by the selective use of GMP was the most cost-effective strategy. From the Canadian perspective, the routine use of the standard therapy, initial thyroid lobectomy, was most cost-effective. From both perspectives, the routine use of GEC only was the least cost-effective. There was no clear survival benefit from any of the strategies. The cost of the GEC and the GMP had a major influence on cost-effectiveness. The routine GEC followed by selective GMP was the most beneficial strategy when the estimated cost of thyroid surgery exceeded $6,686. Cost-effectiveness probability curves showed that none of the strategies had a probability of cost-effectiveness higher than 35% with regard to cost and QALY. The cost-effectiveness probability for GEC alone remained under 10% for all estimates of cost and QALY that ranged from $10,000 to $100,000.
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Conclusions
In the United States, the most cost-effective strategy for managing AUS nodules was routine GEC followed by selective GMP. In Canada, the most cost-effective strategy was standard management starting with diagnostic lobectomy.
ANALYSIS AND COMMENTARY
This is a very interesting theoretical analysis by Canadian investigators who are probably less biased by personal experience than those in the United States, who may be influenced by personal experience or employment by industry. The assumptions about cost seem reasonable. Management was based on ATA guidelines. A key factor that influenced the results was the estimated cost of $9,942 for diagnostic lobectomy and $10,155 for total thyroidectomy in the United States versus $4,205 and $4,483, respectively, in Canada. In the United States, hospital costs are likely to add greatly to the costs, even when the thyroidectomy is performed as same-day surgery, and it is not clear whether this cost was estimated. In another study of cost analysis using a different model, routine gene mutation panel testing was shown to be cost-effective by reducing the need for diagnostic lobectomy followed by total thyroidectomy (3). On the other hand, some thyroid surgeons recommend total thyroidectomy as the initial approach, and this was not considered in the model simulation of the current study.
Some cytopathologists prefer to avoid using the diagnosis of AUS/FLUS, the basis for this analysis. Others recommend that the FNA be repeated when this diagnosis is made, rather than initiating other diagnostic maneuvers or diagnostic surgery. In a large meta-analysis of the Bethesda classification, the AUS/FLUS category made up about 10% of FNA biopsy results; another 10% of the FNA results was the indeterminate category of follicular neoplasm (4) . Nodules in these categories probably deserve study using molecular markers. When the cost of molecular studies is significantly reduced, it is likely that they will be used more widely. Rapid advancement in the methods will improve the sensitivity and negative predictive values for malignancy by molecular markers in the next few years. In the meantime, the current analysis may influence the strategy for the management of thyroid nodules.
